Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA‐REG OUTCOME trial

AIM: To evaluate the effects of empagliflozin versus placebo on subsequent insulin initiation or dosing changes in a large cardiovascular outcomes trial. MATERIALS AND METHODS: In EMPA‐REG OUTCOME, 7020 patients with type 2 diabetes and cardiovascular disease received empagliflozin 10 mg, 25 mg, or...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaduganathan, Muthiah, Inzucchi, Silvio E., Sattar, Naveed, Fitchett, David H., Ofstad, Anne Pernille, Brueckmann, Martina, George, Jyothis T., Verma, Subodh, Mattheus, Michaela, Wanner, Christoph, Zinman, Bernard, Butler, Javed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291462/
https://www.ncbi.nlm.nih.gov/pubmed/34463409
http://dx.doi.org/10.1111/dom.14535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291462/
https://www.ncbi.nlm.nih.gov/pubmed/34463409
http://dx.doi.org/10.1111/dom.14535

Ejemplares similares